Dobutamine for heart failure in wild-type ATTR amyloidosis
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests whether dobutamine, a heart-strengthening medicine, can improve blood flow and symptoms in people with a specific type of amyloidosis that affects the heart and who are already on water pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have wild-type ATTR amyloidosis with heart involvement, confirmed by genetic testing or scans.
- You are 65 years or older.
- You have heart failure symptoms (like shortness of breath or fatigue) that put you in NYHA class II, III, or IV.
- You are taking a water pill (diuretic) called a loop diuretic.
- Your heart's pumping strength is below 50% or your stroke volume index is less than 35 ml/m2.
- You do not have severe aortic valve narrowing, serious coronary artery disease, or end-stage kidney disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows patients with a specific type of heart amyloidosis (wild-type ATTR) who are taking or could start the drug tafamidis. It aims to learn more about how the condition and treatment affect people over time.
This trial tests whether setting your pacemaker to a slightly faster minimum heart rate (the 'lower rate') can improve your heart function and symptoms. It might help by making your heart beat more efficiently, potentially reducing fatigue and shortness of breath.
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
This trial studies whether a structured exercise training program is safe and helpful for people with transthyretin (ATTR) cardiac amyloidosis. It may help improve fitness and daily functioning, and it may also compare groups for specific eligibility needs.
This study tests a personalized exercise program for people with cardiac amyloidosis to see how it affects their heart and daily life. The goal is to help you feel better and stay active safely.
Hear when a new ATTR Amyloidosis Wild Type trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.